Expression of seven stem-cell-associated markers in human airway biopsy specimens obtained via fiberoptic bronchoscopy

Journal of Experimental and Clinical Cancer Research

Volumn 32, Issue 1, 2013, Pages

  Li, Laodong ^a   Yu, Huina ^a   Wang, Xiaoyang ^b   Zeng, Jinrong ^a   Li, Dangyu ^a   Lu, Jingyan ^a   Wang, Changming ^a   Wang, Jiying ^a   Wei, Jianghong ^a   Jiang, Ming ^a   Mo, Biwen ^a  

^a GUILIN MEDICAL UNIVERSITY   (China)

^b VitroVivo Biotechnology   (United States)

Author keywords

Diagnostic marker; Lung cancer; Stem cell associated marker; Therapeutic target

Indexed keywords

BMI1 PROTEIN; CD133 ANTIGEN; HERMES ANTIGEN; MSI2 PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; PROTEIN; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER TISSUE; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; FIBEROPTIC BRONCHOSCOPY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LUNG BIOPSY; LUNG CANCER; LUNG PARENCHYMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; BRONCHOSCOPY; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; GENE EXPRESSION; HUMANS; LUNG; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASTIC STEM CELLS; REPRODUCIBILITY OF RESULTS; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY; STEM CELLS; TUMOR MARKERS, BIOLOGICAL;

EID: 84877829476     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-32-28     Document Type: Article

References (31)

1. Global cancer statistics. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D, CA Cancer J Clin 2011 61 69 90 10.3322/caac.20107 21296855
2. Cancer statistics, 2012. Siegel R, Naishadham D, Jemal A, CA Cancer J Clin 2012 62 10 29 10.3322/caac.20138 22237781
3. Stem cells, cancer, and cancer stem cells. Reya T, Morrison SJ, Clarke MF, Weissman IL, Nature 2001 414 105 111 10.1038/35102167 11689955
4. Cancer stem cells in solid tumours:accumulating evidence and unresolved questions. Visvader JE, Lindeman GJ, Nat Rev Cancer 2008 8 755 768 10.1038/nrc2499 18784658
5. An embryonic stem cell-like signature identifies poorly differentiated lung adenocarcinoma but not squamous cell carcinoma. Hassan KA, Chen G, Kalemkerian GP, Wicha MS, Beer DG, Clin Cancer Res 2009 15 6386 6390 10.1158/1078-0432.CCR-09-1105 19808871
6. Cancer stem cell radioresistance and enrichment: where frontline radiation therapy May fail in lung and esophageal cancers. Nguyen GH, Murph MM, Chang JY, Cancers 2011 3 1232 1252 10.3390/cancers3011232 21603589
7. Lung cancer stem cells. Pine SR, Marshall B, Varticovski L, Dis Markers 2008 24 257 266 10.1155/2008/396281 18525120
8. Diagnostic importance of overexpression of Bmi-1 mRNA in early breast cancers. Saeki M, Kobayashi D, Tsuji N, Kuribayashi K, Watanabe N, Int J Oncol 2009 35 511 515 19639171
9. Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells. Chen YC, Hsu HS, Chen YW, Tsai TH, How CK, Wang CY, et al. PLoS One 2008 3 2637 10.1371/journal.pone.0002637 18612434
10. Progenitor stem cell marker expression by pulmonary carcinomas. Moreira AL, Gonen M, Rekhtman N, Downey RJ, Mod Pathol 2010 23 889 895 10.1038/modpathol.2010.68 20305619
11. Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties. Leung EL, Fiscus RR, Tung JW, Tin VP, Cheng LC, Sihoe AD, et al. PLoS One 2010 5 14062 10.1371/journal.pone.0014062 21124918
12. Urinary cytology and competitive reverse transcriptase-polymerase chain reaction analysis of a specific CD44 variant to detect and monitor bladder cancer. Miyake H, Hara I, Gohji K, Yamanaka K, Arakawa S, Kamidono S, J Urol 1998 160 2004 2008 10.1016/S0022-5347(01)62225-0 9817310
13. Regulatory networks define phenotypic classes of human stem cell lines. Müller FJ, Laurent LC, Kostka D, Ulitsky I, Williams R, Lu C, et al. Nature 2008 455 401 405 10.1038/nature07213 18724358
14. Immunobiomarkers in small cell lung cancer: potential early cancer signals. Chapman CJ, Thorpe AJ, Murray A, Parsy-Kowalska CB, Allen J, Stafford KM, et al. Clin Cancer Res 2011 17 1474 1480 10.1158/1078-0432.CCR-10-1363 21138858
15. Atypical expression and distribution of embryonic stem cell marker, OCT4, in human lung adenocarcinoma. Karoubi G, Cortes-Dericks L, Gugger M, Galetta D, Spaggiari L, Schmid RA, J Surg Oncol 2010 102 689 698 10.1002/jso.21665 20721963
16. Diagnostic relevance of overexpressed nanog gene in early lung cancers. Nirasawa S, Kobayashi D, Tsuji N, Kuribayashi K, Watanabe N, Oncol Rep 2009 22 587 591 19639208
17. Rna-binding protein Musashi2: developmentally regulated expression in neural precursor cells and subpopulations of neurons in mammalian CNS. Sakakibara S, Nakamura Y, Satoh H, Okano H, J Neurosci 2001 21 8091 8107 11588182
18. Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia. Kharas MG, Lengner CJ, Al-Shahrour F, Bullinger L, Ball B, Zaidi S, et al. Nat Med 2010 16 903 908 10.1038/nm.2187 20616797
19. Bronchoscopy for the diagnosis and staging of lung cancer. El-Bayoumi E, Silvestri GA, Semin Respir Crit Care Med 2008 29 261 270 10.1055/s-2008-1076746 18506664
20. Human embryonic stem cell genes OCT4, NANOG, STELLAR, and GDF3 are expressed in both seminoma and breast carcinoma. Ezeh UI, Turek PJ, Reijo RA, Clark AT, Cancer 2005 104 2255 2265 10.1002/cncr.21432 16228988
21. Overexpression of nanog protein is associated with poor prognosis in gastric adenocarcinoma. Lin T, Ding YQ, Li JM, Med Oncol 2012 29 878 885 10.1007/s12032-011-9860-9 21336986
22. Overexpression of nanog predicts tumor progression and poor prognosis in colorectal cancer. Meng HM, Zheng P, Wang XY, Liu C, Sui HM, Wu SJ, et al. Cancer Biol Ther 2010 9 295 302 10.4161/cbt.9.4.10666
23. Expression of NANOG in human gliomas and its relationship with undifferentiated glioma cells. Niu CS, Li DX, Liu YH, Fu XM, Tang SF, Li J, Oncol Rep 2011 26 593 601 21573506
24. Nanog is highly expressed in ovarian serous cystadenocarcinoma and correlated with clinical stage and pathological grade. Pan Y, Jiao J, Zhou C, Cheng Q, Hu Y, Chen H, Pathobiology 2010 77 283 288 10.1159/000320866 21266826
25. Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance. Kikuchi J, Kinoshita I, Shimizu Y, Kikuchi E, Konishi J, Oizumi S, et al. Cancer 2010 116 3015 3024 10.1002/cncr.25128 20564407
26. Prognostic value of CD133 expression in stage I lung adenocarcinomas. Woo T, Okudela K, Mitsui H, Yazawa T, Ogawa N, Tajiri M, et al. Int J Clin Exp Pathol 2010 4 32 42 21228926
27. Sox2 Expression in pulmonary non-small cell and neuroendocrine carcinomas. Sholl LM, Long KB, Hornick JL, Appl Immunohistochem Mol Morphol 2010 18 55 61 10.1097/PAI.0b013e3181b16b88 19661786
28. Evidence that SOX2 overexpression is oncogenic in the lung. Lu Y, Futtner C, Rock JR, Xu X, Whitworth W, Hogan BL, et al. PLoS One 2010 5 11022 10.1371/journal.pone.0011022 20548776
29. Coexpression of oct4 and nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial-mesenchymal transdifferentiation. Chiou SH, Wang ML, Chou YT, Chen CJ, Hong CF, Hsieh WJ, et al. Cancer Res 2010 70 10433 10444 10.1158/0008-5472.CAN-10-2638 21159654
30. Absence of OCT4 expression in somatic tumor cell lines. Cantz T, Key G, Bleidissel M, Gentile L, Han DW, Brenne A, et al. Stem Cells 2008 26 692 697 10.1634/stemcells.2007-0657 18032701
31. Prognostic value of Bmi-1 oncoprotein expression in NSCLC patients: a tissue microarray study. Vrzalikova K, Skarda J, Ehrmann J, Murray PG, Fridman E, Kopolovic J, et al. J Cancer Res Clin Oncol 2008 134 1037 1042 10.1007/s00432-008-0361-y 18264721